B cell Receptor (BCR) plays a pivotal role in providing maturation and survival signals for B cells. However, dysregulation of the BCR pathway is a fundamental characteristic observed in numerous B cell malignancies, including chronic lymphocytic leukemia (CLL), revealing its importance in disease progression. Despite the absence of recurrent mutations found in the BCR-related genes of untreated cases, BCR inhibitors have shown a universal clinical response in CLL patients. We and others have shown that short non-coding RNAs, namely microRNAs, can (dys)regulate the BCR signaling propensity, but it is still unclear if long non-coding RNAs (lncRNAs) play a role in BCRactivation. Hence, we hypothesized that lncRNAs could be involved in BCR-mediated CLL activation. To address our hypothesis, we performed differential lncRNA expression analysis in CLL cells from patients treated with BCR inhibitors and cross-validated in CLL intraclonal subpopulations with high BCR activity (CXCR4dim CD5bright) vs. low BCR activity (CXCR4bright CD5dim). We found 12 lncRNAs related to the BCR pathway inhibition/activity. Out of these lncRNAs, we selected a lncRNA that belongs to a class of lncRNA called long intergenic non-coding RNA (lincRNAs) which often play a role in trans-activating signaling pathways.